Investor Relations

Eton Pharmaceuticals, Inc. is a commercial company focused on developing, acquiring, and commercializing high-potential therapies for the treatment of patients with rare diseases. We have a diversified pipeline of product candidates across multiple therapeutic areas, and a team with significant expertise in bringing products from clinical trials to patients with exceptional speed.

Volume :

Minimum 15 minutes delayed. Source: LSEG

News Releases
Eton Pharmaceuticals Reports Third Quarter 2026 Financial Results
November 5, 2026
Record Q3 2026 product sales of $57.9 million, 158% year-over-year growth; surpassed $200 million annualized revenue run rate goal five quarters ahead of schedule Q3 2026 fully diluted GAAP EPS of $1.06, non-GAAP fully diluted EPS of $0.50; EBITDA of $24.8 million, Adjusted EBITDA of $28.5 million
Read More
Eton Pharmaceuticals Announces Preliminary ET-700 Pilot Study Results Evaluating Copper Absorption Inhibition and Gastrointestinal Tolerability
November 5, 2026
Treatment-related adverse events occurred in 1 of 12 ET-700 participants compared with 8 of 12 GALZIN ® participants Hepatic copper uptake decreased 12% with ET-700, compared with a 46% decrease with GALZIN, and an 11% increase with placebo Company plans additional study arms in 2027 evaluating
Read More
Eton Pharmaceuticals to Present at 2026 Jefferies Global Healthcare Conference in London
November 4, 2026
DEER PARK, Ill., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company’s executive leadership team
Read More
Email Alerts
Eton Latest Events